Boston Scientific Corporation ($BSX) Stock Forecast: Down 5.0% Today

What is Boston Scientific Corporation?

Boston Scientific Corporation (BSX) is a leading medical technology company that specializes in the development of innovative medical solutions that improve the health of patients around the world. The company is known for its diverse portfolio of products in areas such as interventional cardiology, cardiac rhythm management, endoscopy, and neuromodulation.

Why is Boston Scientific Corporation going down?

BSX stock is down 5.0% on May 8, 2026 18:26

• The stock of Boston Scientific Corp. (BSX) experienced a strong bearish movement today, hitting a new 52-week low of $55.94.
• The bearish trend can be attributed to a combination of factors:
• Analyst downgrades despite a modest quarterly beat may have raised concerns among investors about near-term growth and profitability.
• The FDA's classification of a recall of Boston Scientific's Accolade pacemakers as the most serious type due to reported deaths and injuries likely added to investor uncertainty.
• Despite the recent downturn, analysts still maintain a "Moderate Buy" rating on BSX with an average price target of $93.91, citing strong fundamentals amidst market volatility and competitive pressures.
• The overall market sentiment for BSX remains mixed, with institutional investors like Glenview Trust Co increasing their holdings, while analysts issue positive ratings but acknowledge challenges ahead.

BSX Price Chart

BSX Technical Analysis

BSX News

Fund Update: 191,081 BOSTON SCIENTIFIC (BSX) shares added to Glenview Trust Co portfolio

Glenview Trust Co has increased its holdings in BOSTON SCIENTIFIC (BSX) by adding 191,081 shares, according to a recent SEC 13F filing for the Q1 2026 reporting period. This comes amidst significant institutional investor activity in BSX, with 801 institutions increasing and 922 decreasing their positions, while company insiders and members of Congress have also engaged in trading activity. Analysts maintain a generally positive outlook, with several firms issuing "Buy" or "Outperform" ratings and a median price target of $87.5.

https://www.quiverquant.com/news/Fund+Update%3A+191%2C081+BOSTON+SCIENTIFIC+%28BSX%29+shares+added+to+Glenview+Trust+Co+portfolio

Dna Forensic Market Is Booming So Rapidly | Agilent Technologies, Illumina, Bio-Rad Laboratories

A new study by Coherent Market Insights forecasts significant growth in the Dna Forensic Market from 2026 to 2033. The report offers detailed analysis of market dynamics, competitive landscapes, regional performance, and key segments, providing strategic insights for businesses and investors. It covers major players such as Thermo Fisher Scientific, Qiagen, Agilent Technologies, and Illumina, along with market segmentation across various applications like law enforcement, forensic laboratories, and medical research.

https://www.openpr.com/news/4506886/dna-forensic-market-is-booming-so-rapidly-agilent

Boston Scientific Corp. Stock (US10117L1017): Hits 52-Week Low Amid Analyst Downgrades and Guidance

Boston Scientific Corp. (BSX) shares recently hit a new 52-week low of $55.94 following analyst downgrades despite a modest quarterly beat. The stock has plunged approximately 49% from its 52-week high, reflecting investor concerns about near-term growth and profitability. Despite this, analysts maintain a "Moderate Buy" rating with an average price target of $93.91, citing strong fundamentals but acknowledging market volatility and competitive pressures.

https://www.ad-hoc-news.de/boerse/news/ueberblick/boston-scientific-corp-stock-us10117l1017-hits-52-week-low-amid/69291940

Boston Scientific’s pacemaker recall is most serious type: FDA

The FDA has classified a recall of Boston Scientific's Accolade pacemakers as the most serious type due to reported deaths and injuries. The recall aims to correct issues with the devices. This classification signifies a high risk of serious adverse health consequences or death.

https://www.modernhealthcare.com/medical-devices/mh-boston-scientific-fda-accolade-pacemaker-recall-correction/

Spine Surgery Robots Market to Boom Worldwide By 2026-2033|

The global Spine Surgery Robots Market is projected to grow from USD 288.3 million in 2026 to USD 703.9 million by 2033, at a CAGR of 13.6%. A new research report from Coherent Market Insights details this growth, driven by increasing demand and continuous innovation, and provides a comprehensive analysis of market segments, key players, and regional trends. The report aims to offer strategic guidance to industry leaders, investors, and decision-makers by outlining growth drivers, opportunities, and competitive landscapes.

https://www.openpr.com/news/4506291/spine-surgery-robots-market-to-boom-worldwide-by-2026-2033

Trending Today

Marathon Digital Holdings Inc. ($MARA) Stock Forecast: Down 9.9% Today

Digital Ocean Holdings ($DOCN) Stock Forecast: Down 5.2% Today

Applied Materials Inc. ($AMAT) Stock Forecast: Down 5.7% Today

Circle Internet Group ($CRCL) Stock Forecast: Down 5.5% Today

KLA-Tencor Corporation ($KLAC) Stock Forecast: Down 6.0% Today

Humana Inc. ($HUM) Stock Forecast: Up 5.1% Today

Zebra Technologies Corporation ($ZBRA) Stock Forecast: Up 14.7% Today

Philip Morris International Inc ($PM) Stock Forecast: Up 5.0% Today

Super Micro Computer Inc ($SMCI) Stock Forecast: Down 10.1% Today

CDW Corporation ($CDW) Stock Forecast: Down 5.1% Today

Boston Scientific Corporation Price History

21.03.2026 - BSX Stock was down 5.1%

• Boston Scientific Corp. (BSX) saw a bearish market movement today.
• A decision to lower the price target for BSX, based on electrophysiology hospital-purchasing data and mixed reactions to recent trial results, may have influenced the negative market sentiment.
• Concerns about a slightly higher ischemic stroke rate in the trial results could have impacted investor confidence, despite some analysts maintaining positive outlooks on the company.
• Market reaction to uncertainties about BSX's electrophysiology segment performance and the trial results' potential impact on revenue projections likely led to the observed bearish trend today.

24.03.2026 - BSX Stock was down 5.3%

• BSX stock had a bearish movement today, possibly influenced by the comparison trial announcement between Johnson & Johnson's Varipulse Pro PFA platform and Boston Scientific's Farapulse system. Concerns about competition and market share might have impacted investor sentiment.
• Despite the bearish movement, BSX has recently shown strong performance compared to peers and the broader market, indicating resilience and growth potential. This decline could be a temporary setback rather than a long-term trend.
• Analysts maintain a Buy rating on Boston Scientific, emphasizing significant upside potential, suggesting the company's solid fundamentals. Investors may view the current dip as a buying opportunity in anticipation of future growth.

24.03.2026 - BSX Stock was down 5.3%

• Boston Scientific Corp. experienced a notable downward trend in its stock price today, despite receiving positive updates and showing resilience in the market.
• Concerns arose as Johnson & Johnson initiated a direct comparison clinical trial between Varipulse and Boston Scientific's Farapulse for treating atrial fibrillation, potentially impacting market competition and share.
• While the company saw a strong start and reported impressive quarterly net sales, the decline in stock value could be linked to investors taking profits following recent growth.
• The overall market's negative performance today likely also weighed on BSX shares, despite the company's recent market outperformance.

04.01.2026 - BSX Stock was down 13.8%

• Boston Scientific's stock (BSX) saw a significant 17% decline post its Q4 2025 earnings and revenue report.
• Despite surpassing expectations for the quarter, the stock plummeted due to lower-than-anticipated guidance for Q1 2026, raising concerns about the company's short-term outlook.
• The announcement of a $14.5 billion acquisition of Penumbra (PEN) potentially added to investor unease and the subsequent drop in BSX's stock value.
• The market's response indicates a strong emphasis on future guidance and growth prospects, leading to the sell-off of BSX shares despite positive current performance indicators.

04.01.2026 - BSX Stock was down 17.7%

• Reported an increase in profit and sales spurred by strong performance in cardiovascular and MedSurg units, but issued soft guidance for the future period, leading to a decline in share price.
• Despite exceeding earnings expectations, the stock fell significantly due to a disappointing outlook for the current quarter. Cautious 2026 revenue forecast and profit projections, slightly below expectations, contributed to the downtrend.
• Market responded unfavorably to the company's forecast of slower organic revenue growth in 2026, despite exceeding analyst estimates in the fourth quarter. This conservative outlook, alongside the integration of a major acquisition, triggered investor concerns about future growth prospects.

30.02.2026 - BSX Stock was down 5.1%

• Boston Scientific (BSX) experienced a strong bearish movement today.
• The bearish trend could be attributed to the market's reaction to the upcoming conference call discussing the company's first-quarter 2026 results. Investors might be cautious or uncertain about the financial performance and business highlights to be revealed during the call.
• Additionally, the news about the FDA 510(k) clearance for Boston Scientific's Asurys Fluid Management System targeting kidney stone procedure risks might not have been impactful enough to offset the overall negative sentiment surrounding the stock.
• The reaffirmation of a "Strong Buy" rating for First Watch Restaurant Group by Raymond James, despite recent stock decline, could have also diverted investor attention away from Boston Scientific, contributing to the bearish movement.

04.01.2026 - BSX Stock was down 15.6%

• Despite Boston Scientific beating Q4 2025 earnings and revenue estimates, the stock experienced a significant 17% drop due to weaker-than-expected guidance for Q1 2026. This disappointing outlook for the immediate future led to a bearish market movement.
• The slowdown in the growth of the electrophysiology business, particularly in the U.S. market, raised concerns among analysts and investors, contributing to the stock price decline.
• The acquisition of Penumbra for $14.5 billion could have also impacted investor sentiment, as the market may be uncertain about the potential synergies and outcomes of this significant move.
• The cautious outlook provided by Boston Scientific despite reporting increased profit and sales suggests that investors are focusing more on the company's future prospects and guidance, which in this case, did not meet expectations, leading to the bearish movement in the stock.

22.03.2026 - BSX Stock was up 5.7%

• Boston Scientific is a leading medical technology company focused on developing innovative solutions to transform patient lives.
• The stock of Boston Scientific (BSX) experienced a strong bullish movement today.
• The positive market reaction can be attributed to the company's robust first-quarter 2026 results, including significant revenue growth and exceeding earnings expectations.
• Key factors contributing to the bullish sentiment could be the successful clinical trial outcomes, regulatory approvals, and strategic acquisitions announced by Boston Scientific.
• Investors likely responded favorably to the company's updated full-year guidance, reflecting confidence in its growth trajectory and market positioning.

22.03.2026 - BSX Stock was up 7.2%

• Boston Scientific is a leading medical technology company focusing on innovative solutions to enhance patient care. The company has a history of positive clinical trial outcomes and meeting regulatory milestones.
• Net sales for Boston Scientific saw an 11.6% increase in the first quarter of 2026. The company surpassed its earnings per share (EPS) expectations, reflecting strong financial performance.
• Positive results from clinical trials of key medical devices like the WATCHMAN FLX™ and EKOS™ systems have boosted investor confidence in the company's growth trajectory.
• The market reacted favorably to Boston Scientific's optimistic guidance for the full year and second quarter of 2026, signaling expected sales growth and a positive outlook.
• Boston Scientific's robust financial performance and promising future outlook likely drove investor confidence and contributed to the bullish movement in its stock price.

22.03.2026 - BSX Stock was up 5.8%

• Boston Scientific reported impressive first-quarter 2026 results, surpassing expectations with significant revenue growth and positive clinical trial outcomes for key medical devices.
• Despite the positive financial performance, the stock initially experienced a decline, potentially due to broader sector pressure or market participants expecting a normalization in growth after the strong results.
• The appointment of Aamir Paul as the new CEO of Regal Rexnord, a move from Schneider Electric, might have also influenced market sentiment positively, reflecting leadership changes in related industries.
• Overall, Boston Scientific's robust performance and strategic advancements in its product portfolio and regulatory approvals likely contributed to the bullish movement in its stock price today.

22.03.2026 - BSX Stock was up 8.5%

• Despite adjustments to its 2026 guidance related to challenges in its electrophysiology, Watchman, and urology segments, Boston Scientific's stock witnessed a significant bullish movement.
• Market response was likely influenced by the company's strong performance in the first quarter of 2026, marked by substantial revenue growth and positive future outlook.
• Investors may interpret the revised guidance as a proactive measure to tackle present difficulties and position the company for growth, leading to optimistic sentiment towards the stock.
• The market appears to be focusing on Boston Scientific's strategic initiatives and long-term prospects, driving up the stock's value despite the revised projections.

08.04.2026 - BSX Stock was down 5.0%

• The stock of Boston Scientific Corp. (BSX) experienced a strong bearish movement today, hitting a new 52-week low of $55.94.
• The bearish trend can be attributed to a combination of factors:
• Analyst downgrades despite a modest quarterly beat may have raised concerns among investors about near-term growth and profitability.
• The FDA's classification of a recall of Boston Scientific's Accolade pacemakers as the most serious type due to reported deaths and injuries likely added to investor uncertainty.
• Despite the recent downturn, analysts still maintain a "Moderate Buy" rating on BSX with an average price target of $93.91, citing strong fundamentals amidst market volatility and competitive pressures.
• The overall market sentiment for BSX remains mixed, with institutional investors like Glenview Trust Co increasing their holdings, while analysts issue positive ratings but acknowledge challenges ahead.